|Childhood cancer has seen remarkable progress in the last 50 years. Since 1962, the most common form of childhood cancer has gone from a 5% cure rate to a 98.5% cure rate in 2012. Overall, 80% of pediatric cancers are cured.
Despite these improvements, one in five cancer cases still claims a life. New treatments for hepatoblastoma are needed to increase children’s chances of survival, and those advancements happen through the efforts of people who care.
|Though rare, hepatoblastoma is the 8th leading cause of childhood cancer mortality, simply because there is no cure.||You can help kids like Macy by getting involved! Those one in five children who are not cured from pediatric cancer continue to succumb from the same diseases year after year. Currently there is not a cure for hepatoblastoma and no research center in the United States to help find a cure.
We hope to increase the survival rate of children with pediatric cancer by funding research and to bring a research center to the United States.
Research Update (March, 2016)
Dr. Vasudevan Receives Grant for Liver Cancer Research
The Macy Easom Cancer Research Foundation has awarded Sanjeev Vasudevan, M.D., a pediatric surgeon at Texas Children’s Hospital, a $75,000 grant for research into a form of pediatric liver cancer called hepatoblastoma. It is a disease that usually affects children under the age of five.
Dr. Vasudevan’s research uses new imaging techniques to investigate intra-operative, real-time visualization of a tumor and blood vessels. These imaging techniques will allow surgeons to look at the actual structure of the liver during surgery without relying on previous scans that may not show the immediate condition of the liver.
Read the full article
Research Update (Sept. 10, 2014)
We are excited to announce the 3rd Annual Macy Michelle Easom Memorial Lectureship will be held on October 13 at Oregon Health & Science University in Portland, Oregon. We are excited to have Dr. Carlos Rodriguez-Galindo from Harvard University as our speaker. Dr. Carlos Rodriguez-Galindo is chair of the Children’s Oncology Group ‘Rare Tumors’ committee, which has the responsibility of designing clinical trials for hepatoblastoma in North America, Australia, New Zealand and Switzerland. The lectureship provides an opportunity for world-renowned cancer and stem cell doctors and scientists to meet and discuss research findings and next steps. We are thankful for our research partnership with OSHU Knight Cancer Institute and for the opportunity to host another lectureship. For every dollar given to MECRF, 98% goes directly into research. We will be attending the lectureship and will provide updates once we return! For more information on Dr. Carlos Rodriguez-Galindo, you can read his biography here.
Research Update (Sept. 3, 2014)
Because of you – our Macy Easom Cancer Research Foundation supporters – we have great news for cancer research! We cannot thank you enough for your generous donations and contributions. For every dollar given to MECRF, 98% goes directly into research. Our research institute, the OHSU Knight Cancer Institute, along with Dr. Charles Keller and Dr. Brian Druker, are making vast strides in their hepatoblastoma and liver cancer research project. The OHSU Knight Cancer Institute has announced a $100 million anonymous gift to the Knight Cancer Challenge. This gift is a strong vote of confidence in the vision the Knight Cancer Institute has developed to enhance early detection and treatment of cancer. This gift combined with the generosity of so many others, including donations from our foundation, and the State of Oregon’s $200 million investment in research facilities, means the Knight Cancer Institute is more than $415 million into their effort to raise $500 million. This progress is incredible and will allow the Knight Cancer Institute to make an impact for patients more quickly.
Research Update (Feb. 10, 2014)
An international academic-industry partnership is well underway to create a humanized hepatoblastoma mouse model – that is, a mouse whose liver has not only normal human liver cells but also childhood hepatoblastoma tumor cells. Such a model could be used to test new drugs to treat this childhood liver tumor. Xentech scientist Dr. Stefano Cairo contributes the tumor cells and hepatoblastoma expertise. Yecuris Corporation, a world leader in this area, contributes the expertise of generating human liver models in mice. Yecuris’ founder, Dr. Markus Grompe, is a faculty member at Oregon Health & Science University (OHSU). On the academic side, OHSU childhood cancer researcher, Dr. Charles Keller, assists in drug discovery for the disease.
“The best we can do to help children with cancer is to render preclinical research so reliable that immediate translation into clinical acts will be possible. This joint effort will hopefully serve this purpose,” says Dr. Cairo.
Research Update (Dec. 31, 2013)
We were very blessed and honored to be able to provide Dr. Charles Keller and the Knight Cancer Institute with $75,000 at the 2nd Annual Macy Michelle Easom Memorial Lectureship on September 10 at Oregon Health and Science University. This money was to help fund hepatoblastoma and liver cancer research. We are very excited to share the research progress that has been made! Dr. Keller and his dedicated team are working with Dr. Stefano Cairo from Xentech in Paris, France. Dr. Cairo has provided hepatoblastoma tissue that is currently being cultured. If all goes well, some of the tissue will be able to start being drug tested, while the remaining tissue will be established into a “humanized” mouse model. The mouse model will be able to receive the drugs that had the best results on the tissue that was drug tested. We are very excited for the progress that has been made. We are also in the process of beginning work with a researcher at Harvard. As always, research does take time and there are many variables to factor. We are excited to get updates on the progress. Thank you so much to all of our wonderful supporters who helped make this possible!! One step closer to a cure!
The 2nd Annual Macy Michelle Easom Memorial Lectureship
We are excited to announce we met with world-renowned cancer and steam cell doctors and scientists at the Second Annual Macy Michelle Easom Memorial Lectureship on September 10, 2013 at Oregon Health and Science University in Portland, Oregon. Klaus H. Kaestner, Ph.D. was our speaker. Dr. Kaestner is from the University of Pennsylvania School of Medicine and is a senior leader in the field of liver biology. We were very excited to present Charles Keller, M.D. and the Knight Cancer Institute with $75,000 to help fund hepatoblastoma and liver cancer research. We want to thank our foundation supporters for helping make this possible. We hope you will continue to help us in our mission of finding a cure for hepatoblastoma.
Macy Easom Memorial Lectureship
We met with world-renowned cancer and stem cell doctors and scientists for the Macy Easom Memorial Lectureship at Oregon Health & Science University in Portland, Ore. on Tuesday, June 5. We were able to meet with researchers and doctors who are working on finding cures for pediatric cancer, especially hepatoblastoma. To help reach our mission, we spent two days touring the OHSU Pediatric Cancer Biology program, the OHSU Knight Cancer Institute, the Keller Laboratory and the Grompe Lab. Our foundation also presented its mission at the Macy Easom Memorial Lectureship where partner Stefano Cairo, Ph.D., a human geneticist at XenTech in Paris, France, discussed the important aspects of hepatoblastoma clinical care and research with 60-75 cancer and stem cell doctors and scientists.